

Use and Outcomes of Kidneys from Donation after Circulatory Death Donors in the United States

John Gill,^{*†} Caren Rose,^{*†} Julie Lesage,^{*} Yayuk Joffres,^{*} Jagbir Gill,^{*†} and Kevin O'Connor[‡]

^{*}Division of Nephrology, University of British Columbia, St. Paul's Hospital, Vancouver, British Columbia, Canada;

[†]Centre for Health Evaluation and Outcomes Sciences, Vancouver, British Columbia, Canada; and [‡]LifeCenter Northwest, Seattle, Washington

ABSTRACT

Donation after circulatory death (DCD) donors are an important source of kidneys for transplantation, but DCD donor transplantation is less common in the United States than in other countries. In this study of national data obtained between 2008 and 2015, recovery of DCD kidneys varied substantially among the country's 58 donor service areas, and 25% of DCD kidneys were recovered in only four donor service areas. Overall, 20% of recovered DCD kidneys were discarded, varying from 3% to 33% among donor service areas. Compared with kidneys from neurologically brain dead (NBD) donors, DCD kidneys had a higher adjusted odds ratio of discard that varied from 1.25 (95% confidence interval [95% CI], 1.16 to 1.34) in kidneys with total donor warm ischemic time (WIT) of 10–26 minutes to 2.67 (95% CI, 2.34 to 3.04) in kidneys with total donor WIT >48 minutes. Among the 12,831 DCD kidneys transplanted, kidneys with WIT ≤48 minutes had survival similar to that of NBD kidneys. DCD kidneys with WIT >48 minutes had a higher risk of allograft failure (hazard ratio, 1.23; 95% CI, 1.07 to 1.41), but this risk was limited to kidneys with cold ischemia time (CIT) >12 hours. We conclude that donor service area-level variation in the recovery and discard of DCD kidneys is large. Additional national data collection is needed to understand the potential to increase DCD donor transplantation in the United States. Strategies to minimize cold ischemic injury may safely allow increased use of DCD kidneys with WIT >48 minutes.

J Am Soc Nephrol 28: 3647–3657, 2017. doi: <https://doi.org/10.1681/ASN.2017030238>

Donation after circulatory death (DCD) donors are an increasingly important source of transplantable organs. The proportion of DCD kidney donors in the United States increased from 7.3% in 2005 to 17.7% in 2015.¹ However, kidney transplantation from DCD donors in the United States remains lower than in other countries, where DCD donors are also primarily Maastricht Criteria Category 3 donors (*i.e.*, controlled donors).² For example, in 2013, 13.6% of deceased donor kidney transplants in the United States were from DCD donors compared with 40% in the United Kingdom.^{3,4}

Unlike kidneys from neurologically brain dead (NBD) donors, DCD donor kidneys are subject to warm ischemic injury that increases the risk of delayed graft function (DGF) and may compromise long-term allograft survival. Therefore, warm ischemic time (WIT) may be an important factor affecting

the acceptance of DCD donor kidneys for transplantation. In addition, donor service area (DSA)-level variation in acceptance practices is an important factor in the use of NBD donor kidneys for transplantation and may also be important in the DCD setting.⁵

Given the increasing importance of DCD donors, we undertook this study to determine contemporary use and outcomes of DCD donor kidneys for

Received March 3, 2017. Accepted July 15, 2017.

Published online ahead of print. Publication date available at www.jasn.org.

Correspondence: Dr. John Gill, Division of Nephrology, University of British Columbia, Providence Building Ward 6a, 1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6. Email: jgill@providencehealth.bc.ca

Copyright © 2017 by the American Society of Nephrology




Figure 1. The controlled DCD procedure showing metrics of ischemic injury, including (1) total donor WIT calculated from the time of WLST to the initiation of cold perfusion, (2) functional WIT defined from onset of sustained hypotension and hypoxia to initiation of perfusion, (3) time to death defined from WLST to declaration of death, and (4) agonal phase defined from onset of sustained hypotension and hypoxia to cessation of circulation. The no touch period is typically of 5 minutes in duration.

transplantation in the United States and specifically focused on the effect of total donor WIT (defined as time from withdrawal of life-sustaining therapy (WLST) to the initiation of cold perfusion) (Figure 1) and DSA-level practice variation.

RESULTS

Recovery of DCD Kidneys

Between January 1, 2008 and December 2, 2015, there were *n*=16,027 kidneys recovered from DCD donors ≥20 kg (*n*=107 kidneys from DCD donors <20 kg were excluded from study). Among the *n*=58 DSAs, the number of DCD kidneys recovered varied from 0 to 1072 (median =216), 25% of DSAs recovered fewer than ten DCD kidneys per




Figure 2. Variation in the proportion of DCD kidneys. The proportion of kidneys recovered from DCD donors varied from 1% to 32% (median =13%; quartile 1, quartile 3 =8, 19) between the 57 DSAs that recovered at least one DCD kidney during the study period.

year, and 25% of all DCD kidneys were recovered in only four DSAs. Among DSAs that recovered at least one DCD kidney, the proportion of kidneys recovered from DCD donors varied from 1% to 32% (median =13%; quartile 1, quartile 3 =8, 19) between DSAs (Figure 2).

DSA Characteristics and Use of DCD Donors

Table 1 compares selected DSA characteristics between DSA quartiles defined by the proportion of DCD donors among all deceased donors identified in the DSA during the study period. The time between the date of hospital referral of a potential donor to the organ procurement organization (OPO) and date of declaration of death was clinically similar in DSA quartiles ranked

by the proportion of DCD donors. The donor conversion rate, defined as the proportion of eligible donors converted to actual NBD donors, was also similar between DSAs quartiles. The proportion of DCD donor kidneys shipped outside the DSA for transplantation was higher in DSAs with a lower proportion of DCD donors during the study period.

Discard of DCD Kidneys

Among recovered DCD kidneys, *n*=3196 (20%) were discarded. In comparison, *n*=17,221 of the 94,047 (18%) recovered NBD kidneys were discarded (*P*<0.001). The proportion of DCD kidneys discarded in a DSA varied between 3% and 33% (Figure 3) and was related to the proportion of NBD kidneys discarded within individual DSAs (Pearson correlation coefficient =0.61; *P*<0.001). In 34 of 58 DSAs, the DCD discard rate was higher than the NBD discard rate (denoted by the black circles in Figure 3).

Table 2 shows the proportion of DCD kidneys discarded in the DSA at the 10th and 90th percentiles of discard in subgroups defined by total donor WIT, kidney donor profile index (KDPI), use of machine perfusion, and use of donor biopsy. Discard was more variable among donor kidneys with a longer total donor WIT, kidneys with higher KDPI, kidneys not treated with machine perfusion, and kidneys evaluated by biopsy.

Table 3 compares the proportion of DCD and NBD kidneys discarded. In the first, second, and third KDPI quartiles, the proportion of DCD discards was higher than the proportion of NBD discards, suggesting that DCD kidneys may have been considered inferior to NBD kidneys with the same KDPI, although DCD is accounted

Table 1. Association of selected DSA characteristics with DCD donation

Proportion of DCD Donors among All Deceased Donors Recovered during Study Period	Time (d) between Date of Hospital Referral of the Potential Donor to OPO and Date of Declaration of Death	Donor ^a Conversion Rate, %	Proportion of DCD Kidneys Shipped outside the DSA
All OPOs 10.7%	2 (1, 4)	73.2 (69.9, 77.3)	14
Quartile 1 <6.3%	3 (2, 5)	71.6 (69.0, 77.7)	17
Quartile 2 6.3%–10.3%	3 (1, 4)	73.9 (69.2, 76.0)	16
Quartile 3 10.4%–14.7%	2 (1, 4)	74.0 (70.2, 80.3)	12
Quartile 4 >14.7%	2 (1, 4)	70.7 (69.1, 77.3)	14
<i>P</i> value for comparison between OPO quartiles	<0.001 ^b	0.60 ^b	<0.001 ^c

Medians (quartile 1, quartile 3) are shown for time and donor conversion rate. Percentages are shown for proportions.

^aDonor conversion rate defined as the proportion of eligible donors converted to NBD donors reported by the SRTR for the years 2013–2015.

^bComparison between OPO quartiles performed using the Kruskal–Wallis test.

^cComparison between OPO quartiles performed using the chi-squared test.

for in the calculation of the KDPI, and DCD kidneys otherwise have more favorable donor characteristics than NBD donor kidneys with the same KDPI. Considering individual factors, the proportion of DCD discards was higher in most subgroups, with the largest difference in DCD versus NBD discard observed among hepatitis C antibody–positive donor kidneys and kidneys not treated with machine

perfusion. The proportion of DCD versus NBD discards did not differ in subgroups defined by factors associated with an increased risk of DGF or allograft failure, such as donor age ≥ 65 years old, terminal serum creatinine >1.5 mg/dl, donor history of hypertension, or diabetes. Kidneys evaluated by a biopsy were the only subgroup in which the proportion of DCD discards was lower than the proportion of NBD discards.

A longitudinal increase in DCD versus NBD discard was not observed, and the proportion of DCD discards did not increase over time in any of the subgroups examined (data not shown).




Figure 3. The proportion of DCD donor kidneys discarded was correlated with the proportion of NBD donor kidneys discarded within DSAs (Pearson correlation coefficient = 0.66; $P=0.001$). DSAs in which the proportion of DCD kidneys discarded was greater than the proportion of NBD kidneys discarded are denoted by black circles.

Total Donor WIT and Discard

The total donor WIT could not be calculated for $n=560$ DCD kidneys. Among the 15,467 kidneys for which total donor WIT could be calculated, the times ranged from 10 to 174 minutes, and the 50th, 75th, and 90th percentiles of WIT were 26, 34, and 48 minutes, respectively. Time to death (calculated from time of withdrawal to time of death) (Figure 1) was a median of 69%, and quartile 1, quartile 3 = 57, 81 of the total donor WIT. The proportions of DCD kidneys discarded with total donor WIT of 10–26, 27–34, 35–48, and >48 minutes were 16%, 20%, 25%, and 29%, respectively.

Table 4 shows that DCD kidneys had a higher-adjusted odds of discard compared with NBD kidneys and that the odds of discard were higher in DCD kidneys with longer total donor WITs. Figure 4 shows that the higher odds of discard among DCD kidneys compared with NBD kidneys varied between KDPI subgroups by total donor WIT. When total donor WIT was >48 minutes, DCD kidneys had higher odds of discard in all KDPI subgroups. With the exception of kidneys in the

Table 2. Variation in DCD kidney discard between DSAs

Group	No. of kidneys	Discarded in This Subgroup, %	Discarded in DSA at the 10th Percentile, %	Discarded in DSA at 90th Percentile, %
All DCD kidneys	16,027	20	11.9	27.8
WIT, ^a min				
10–26	7813	16.1	8.5	28.0
27–34	3948	20.0	8.6	31.1
35–48	2236	24.9	0	61.1
>48	1470	28.9	0	54
KDPI, %				
0–25	2731	5.1	0	14.3
26–50	4798	8.8	3	15.6
51–75	5095	21.0	10.9	30.8
76–100	3403	46.0	30.8	65.4
Machine perfusion	11,860	17.4	5.6	27.4
No machine perfusion	4167	27.1	13.9	62.2
Biopsy	9982	26.3	6.7	38.2
No biopsy	6045	9.4	3.8	20.0

^aWIT could be calculated for n=15,467 DCD kidneys.

KDPI 0%–25% group, the threshold of total donor WIT associated with a higher odds of DCD kidney discard was 27 minutes (the 95% confidence interval for kidneys with total donor WIT 27–34 minutes and KDPI 76%–100% crossed 1.0 because of a limited number of kidneys in this group; n=334).

Table 5 shows factors associated with DCD kidney discard after accounting for DSA-level variation in discard practices. Longer total donor WIT, donor age ≥18 years old (compared with donors 12–17 years old), women donors, body mass index <25 kg/m², donor hypertension, diabetes, nontraumatic cause of death, terminal serum creatinine >1.5 mg/dl, hepatitis C antibody positivity, use of donor biopsy, and nonuse of machine perfusion were associated with a higher odds of discard.

Kidney Transplant Outcomes

The cumulative incidence of all-cause graft loss (ACGL), death-censored graft loss (DCGL), and death with a functioning graft (DWFG) in DCD donor recipients grouped by total donor WIT compared with NBD donor recipients is shown in Figure 5. In these unadjusted analyses, the incidence of ACGL and DWFG was higher in patients who received a DCD donor transplant with total donor WIT of 34–48 and >48 minutes. The 1-year cumulative incidence rates of ACGL in DCD recipients with total donor WIT 34–48 and >48 minutes were 9.0% and 8.9% compared with 6.7% in NBD recipients (including the 3.3%, 3.1%, and 2.2% of patients who had primary nonfunction in each of these groups, respectively).

Table 6 shows that there was no difference in adjusted risk of ACGL, DCGL, or DWFG in DCD donor recipients with total donor WIT ≤48 minutes compared with patients who received an NBD donor transplant. DCD recipients with total donor WIT >48 minutes had an increased risk of ACGL and DWFG but were not at increased risk for the outcome of DCGL compared with NBD donor recipients.

Of interest, the n=1035 DCD recipients with total donor WIT >48 minutes were not at increased risk of ACGL when cold ischemia time (CIT) was <12 hours (hazard ratio, 1.17; 95% confidence interval, 0.84 to 1.62) but were at increased risk for ACGL when CIT was ≥12 hours (hazard ratio, 1.25; 95% confidence interval, 1.07 to 1.45; P=0.02 for the interaction of DCD recipients with total donor WIT >48 minutes × CIT). We were unable to determine the adjusted risk of ACGL in the subgroup of DCD recipients with total donor WIT >48 minutes who were also treated with machine perfusion due to the small number of patients in this group (n=177). The association of total donor WIT >48 minutes with ACGL was consistent in subgroups with KDPI ≥26% (Table 7).

DISCUSSION

The study identifies opportunities to increase the utilization of DCD donor kidneys for transplantation but also highlights the need for additional national data to improve understanding of DCD donor kidney utilization. We found dramatic DSA-level variation in both the recovery of DCD kidneys and the discard of recovered DCD kidneys. Understanding of the reasons for the DSA-level variation in the recovery of DCD donors remains incomplete in our analysis. Failure to wait for patients with severe brain injury to progress to neurologic brain death could inflate the proportion of DCD donors; however, we found no evidence that this was a factor contributing to the observed DSA-level variation in use of DCD donors. We also did not find an association between OPO performance in recovery of NBD donors and recovery of DCD donors. DSAs with lower utilization of DCD donors more frequently shipped DCD donor kidneys to transplant centers outside their DSA, suggesting that regional differences in acceptance of DCD donor organs

Table 3. Discard of DCD and NBD kidneys

Donor Characteristic	DCD No. of Kidneys in Group/% Discard	NBD No. of Kidneys in Group/% Discard	P Value
All	16,027/20	94,047/18	<0.001
KDPI quartile, %			
0–25	2731/5	25,750/3	<0.001
26–50	4798/9	23,208/7	<0.001
51–75	5095/21	20,835/17	<0.001
76–100	3403/46	24,254/47	0.31
Age, yr			
<12	309/10	2030/3	<0.001
12–17	771/6	5184/3	<0.001
18–39	6086/10	36,120/7	<0.001
40–49	3847/20	18,385/16	<0.001
50–59	4260/33	19,658/27	<0.001
60–64	644/46	6385/42	0.04
≥65	110/59	6285/61	0.65
Body mass index, kg/m ²			
<25	729/18	3686/13	<0.001
25–29.9	5104/17	32,876/14	<0.001
≥30	10,194/22	57,485/21	0.25
Men	10,459/18	55,429/16	<0.001
Women	5568/24	38,618/22	0.001
Black	1121/22	15,773/21	0.47
Nonblack	14,906/20	78,274/18	<0.001
History of HTN	4421/34	31,018/35	0.21
History of diabetes	1246/43	9522/45	0.41
Cause of death			
Anoxia	6876/20	23,060/17	<0.001
CVA	3167/31	35,369/28	0.001
Head trauma	5140/12	33,220/9	<0.001
Other	844/25	2398/13	<0.001
Preterminal Cr, mg/dl			
≤1.5	14,190/18	74,801/14	<0.001
>1.5	1837/33	19,246/35	0.19
Hepatitis C antibody	399/67	3955/49	<0.001
Machine perfusion	11,860/17	29,228/17	0.13
No machine perfusion	4167/27	64,819/19	<0.001
Biopsy	9982/26	47,132/32	<0.001
No biopsy	6045/9	46,915/5	<0.001
Year			
2008–2009	3257/22	23,531/18	<0.001
2010–2011	3747/19	23,710/18	0.59
2012–2013	4228/21	23,612/18	<0.001
2014–2015	4795/19	23,194/19	0.52

HTN, hypertension; CVA, cerebrovascular accident; Cr, creatinine.

contribute to differences in the use of DCD donors. Further studies are needed to understand the DSA-level variation in DCD donors observed in our study. Compared with NBD kidneys, DCD kidneys had a higher odds of discard; the odds of discard were greatest in DCD kidneys with total donor WIT >48 minutes, but DCD kidneys with shorter total donor WITs also had a higher odds of discard in subgroups with KDPI >25%. Total donor WIT was independently associated with DCD discard, but among DCD kidneys used for transplantation, only those with total donor WIT >48 minutes were at increased risk of allograft failure; also, there was no evidence that total donor WIT had a differential effect on

allograft failure in kidneys of different quality defined by KDPI quartile. The increased risk of allograft failure in DCD kidneys with total donor WIT >48 minutes was limited to patients with CIT >12 hours, suggesting the importance of strategies to limit CIT.

There is limited information regarding the utilization of DCD kidneys. In an analysis of 62,983 deceased donor kidneys recovered in the United States between 1999 and 2005, DCD donor kidneys had a threefold higher odds of discard compared with NBD donor kidneys.⁵ This study was conducted in an era when experience with DCD was limited and only 4.1% of the kidneys were from DCD donors. In an analysis of $n=896$ DCD

Table 4. Adjusted odds of discard for deceased donor kidneys (n=110,074, including n=15,467 DCD and n=94,047 NBD kidneys)

Factor	Odds Ratio	95% CI
NBD	1.00	
DCD total donor WIT, min		
10–26	1.25	1.16 to 1.34
27–34	1.34	1.23 to 1.47
35–48	1.72	1.54 to 1.92
>48	2.67	2.34 to 3.04
KDPI, %		
0–25 (Reference)	1.00	
26–50	1.94	1.79 to 2.11
51–75	4.10	3.78 to 4.44
76–100	14.67	13.55 to 15.88
Machine perfusion (reference: none)	0.47	0.45 to 0.49
Biopsy (reference: no biopsy)	2.96	2.81 to 3.11
Year		
2008–2009 (Reference)	1.00	
2010–2011	1.01	0.96 to 1.06
2012–2013	1.04	0.99 to 1.10
2014–2015	1.07	1.02 to 1.12

95% CI, 95% confidence interval.

kidneys that met expanded criteria donor criteria (*i.e.*, ECD/DCD kidneys) in the Scientific Registry of Transplant Recipients (SRTR) between 2000 and 2011, 48% were discarded.⁶ Neither study examined the association of WIT or DSA-level practice variation with DCD kidney utilization. In addition to WIT and DSA-level practice variation, the study confirmed nonuse of machine perfusion and use of donor biopsy as potentially modifiable factors associated with the kidney discard.⁵

Our study determined WIT from the time of withdrawal of WLST until the onset of cold perfusion (also known as the total donor WIT),⁷ which should be differentiated from functional WIT that attempts to capture the onset of significant ischemia injury to donor organs by the use of vital signs, such as a sustained drop in the donor’s BP or hypoxia (Figure 1). The threshold of BP and oxygenation at which organs sustain significant ischemic insult is likely affected by a variety of factors, including the age of the donor, leading to a variety of definitions of the functional ischemic time in the literature.^{8–11} Although the SRTR reports the estimated functional WIT, these data are not validated and defined by sustained onset of unstable physiologic parameters that often fluctuate and may render the data inaccurate. We, therefore, elected to use the total donor WIT, because it is reliably defined from the time of WLST. Current recommendations suggest that total donor WIT should not exceed 60 minutes for kidney transplantation.^{12,13} However, these recommendations assume the onset of significant ischemia rapidly after WLST (Figure 1), which may or may not occur in individual potential DCD donors. It is important to recognize that the total donor WITs reported in this study may include periods of time when the donor organs were not subject to significant ischemic insult. There is limited evidence that functional WIT may be a more important determinant of transplant outcome than total donor WIT.¹⁰ However, the upper limit of functional WIT compatible with successful kidney transplantation remains uncertain. Reid *et al.*¹⁴ reported that an agonal phase duration up to 60 minutes (*i.e.*, the time between the onset of hemodynamic and respiratory instability until circulatory arrest in Figure 1) was not associated with an increased risk of adverse outcomes, including DGF and lower kidney allograft function, at 12




Figure 4. DCD kidneys with total donor WIT >27 minutes had a higher adjusted odds of discard compared with NBD donor kidneys when the Kidney Donor Profile Index (KDPI) ≥ 26%.

Table 5. Factors associated with DCD discard

Factor	HR (95% CI)
DCD total donor WIT, min	
10–26	1.00
27–34	1.10 (0.98 to 1.23)
35–48	1.42 (1.25 to 1.61)
>48	2.21 (1.91 to 2.56)
Donor age, yr	
<12	1.49 (0.90 to 2.47)
12–17	1.00
18–39	1.44 (1.04 to 2.00)
40–49	2.45 (1.76 to 3.42)
50–59	4.50 (3.23 to 6.28)
60–64	8.09 (5.60 to 11.68)
≥65	14.15 (8.41 to 23.79)
Donor sex: woman	1.29 (1.18 to 1.39)
BMI, kg/m ²	
<25	1.44 (1.13 to 1.84)
25–29.9	1.00
≥30	0.95 (0.86 to 1.05)
Race	
Nonblack	1.00
Black	0.95 (0.80 to 1.12)
History of hypertension	1.74 (1.57 to 1.92)
History of diabetes	2.10 (1.83 to 2.42)
Cause of death	
Anoxia	1.29 (1.15 to 1.45)
CVA	1.69 (1.48 to 1.92)
Head trauma	1.00
Other	1.73 (1.41 to 2.11)
Preterminal Cr, mg/dl	
≤1.5	1.00
>1.5	3.13 (2.75 to 3.55)
Hepatitis C antibody positive	13.27 (10.43 to 16.89)
Machine perfusion	0.42 (0.38 to 0.47)
No machine perfusion	1.00
Donor biopsy	1.83 (1.62 to 2.06)
Year of donation	
2008–2009	1.00
2010–2011	0.94 (0.82 to 1.07)
2012–2013	1.08 (0.95 to 1.23)
2014–2015	0.93 (0.82 to 1.05)

Multivariate logistic regression model that accounts for difference in DSA-level variation in discard. HR, hazard ratio; 95% CI, 95% confidence interval; BMI, body mass index; CVA, cerebrovascular accident; Cr, creatinine.

ability in the time to cessation of circulatory function in prospective DCD donors.¹⁶ Most DCD protocols in the United States recommend a maximal period of 60 minutes from WLST to circulatory arrest.^{7,12} Potential donors may maintain hemodynamic stability for significant periods of time after WLST. Therefore, the 60-minute limit on the basis of practical considerations, including the feasibility of reserving valuable health care resources such as surgical teams and operating room resources, may lead to premature discontinuation of DCD withdrawal protocols and nonrecovery of transplantable kidneys. In a single-center analysis from the United Kingdom, a protocol of extending the minimum waiting

time after WLST from 1 to 4 hours resulted in a 30% increase in DCD kidney transplantation.¹⁴ In a recent study of nearly 300 DCD kidney transplants at the University of Wisconsin, extending the waiting time from WLST to declaration of death to 2 hours resulted in 9.8% more transplants.¹⁷ The current SRTR OPO performance metrics evaluating the conversion of potential donors to actual donors are limited to NBD donors. The large DSA-level variation in the recovery of DCD kidneys in our study highlights the need for additional national data capture including potential DCD donors who do not progress to circulatory arrest during the current 60-minute time limit to fully understand the opportunity for increasing the utilization of DCD kidneys for transplantation in the United States.

Despite a higher incidence of DGF, DCD kidney transplant function and survival are generally reported as comparable with those from NBD donors.^{18–21} Our findings extend these observations by examining the effect of total donor WIT on DCD transplant outcomes. The study findings of a minimal effect of total donor WIT on kidney transplant outcomes until total donor WIT exceeded 48 minutes and the absence of a differential effect of total donor WIT on outcomes in kidneys of varying quality are provocative but should be interpreted with the understanding that these observations are among kidneys that were carefully selected for transplantation. The observation that the association of total donor WIT >48 minutes with allograft failure was mitigated in patients with CIT <12 hours challenges current recommendations that CIT be limited to 24 hours for DCD kidneys.¹² Previous work has shown that DCD kidneys tolerate CIT poorly, and strategies to minimize CIT to <12 hours may lead to increased utilization of DCD kidneys.^{22,23} We did not find a differential effect of total donor WIT >48 minutes on allograft survival in kidneys with higher KDPI, suggesting that there is potential to safely increase utilization of high-KDPI kidneys with total donor WIT >48 minutes.

In summary, there was large DSA-level variation in the recovery and discard of DCD kidneys in the United States. DCD kidneys had a higher odds of discard compared with NBD kidneys, and longer total donor WITs were associated with DCD discard. However, only total donor WIT >48 minutes was associated with a modest increased risk of allograft failure, and this risk may be modified by limiting CIT to <12 hours. Overall, DCD kidneys provided excellent allograft survival, with 5-year survival of 75% even among kidneys from donors >48 minutes. Improved national data collection is needed to inform future strategies to increase kidney transplantation from DCD donors in the United States.

CONCISE METHODS

This study was approved by our hospital research ethics board and adheres to the Declaration of Istanbul.




Figure 5. The incidence of all cause graft failure, and death with a functioning graft was higher in patients who received a DCD donor transplant with total donor warm ischemic time of 34–48 and > 48 minutes. Cumulative incidence curves including 76,826 NBD kidney transplant recipients. The numbers of DCD recipients in subgroups with total WIT 10–26, 27–34, 34–48, and >48 minutes were 6555, 3160, 1680, and 1044, respectively.

Data Source and Study Inclusion Criteria

This analysis is on the basis of data from the SRTR from January 1, 2008 to December 2, 2015. The SRTR data system includes data on all donors, waitlisted candidates, and transplant recipients in the United States submitted by the members of the Organ Procurement and Transplantation Network (OPTN). The Health Resources and Services Administration, US Department of Health and Human Services provides oversight to the activities of the OPTN and SRTR contractors. Only kidneys from deceased donors weighing ≥ 20 kg (>99% of total donor population) were included in this analysis. The study included $n=356$ kidneys from $n=712$ (2%) uncontrolled DCD donors. Survival analyses excluded multiorgan and dual transplant recipients.

Definitions

Total Donor WIT

The SRTR reports information to allow the calculation of the total donor WIT defined as the time from WLST until the time when core cooling is initiated (Figure 1).

DSA

DSA is an area designated by the Centers Medicare and Medicaid Services to be served by a single OPO.

Discard

A deceased donor kidney was considered discarded if it was recovered for the purposes of transplantation but was not used for transplantation. Dual kidney transplants (*i.e.*, the transplantation of two kidneys into a single donor) were not counted as discards.

The KDPI

The KDPI was determined by calculating the ten-variable Kidney Donor Risk Index (KDRI). Cut points for KDPI quartiles were on the basis of the standardized 2015 KDRI values of deceased kidney donors recovered for transplantation.¹¹

Primary Nonfunction

Primary nonfunction was defined by the outcome of death-censored allograft failure within 90 days of transplantation.

Table 6. Multivariate Cox regression models showing the risk of ACGL, DCGL, and DWFG in recipients of kidney transplant from a DCD donor with increasing total donor WIT compared with NBD donor kidney transplant recipients

Factor	HR (95% CI)		
	ACGL	DCGL	DWFG
NBD	1.00	1.00	1.00
DCD WIT, min			
10–26	0.96 (0.88 to 1.02)	0.91 (0.83 to 1.00)	1.01 (0.89 to 1.07)
27–34	1.09 (0.98 to 1.23)	1.05 (0.90 to 1.24)	1.14 (0.97 to 1.35)
35–48	1.23 (1.07 to 1.41)	1.07 (0.87 to 1.31)	1.39 (1.15 to 1.68)
>48			
Recipient age, yr			
18–39	1.00	1.00	1.00
40–59	0.97 (0.92 to 1.02)	0.65 (0.62 to 0.69)	2.25 (2.04 to 2.48)
≥60	1.41 (1.34 to 1.49)	0.71 (0.66 to 0.76)	4.15 (3.76 to 4.59)
Recipient: woman	0.91 (0.88 to 0.94)	0.97 (0.92 to 1.01)	0.86 (0.82 to 0.91)
Recipient race			
White	1.00	1.00	1.00
Black	1.03 (0.99 to 1.07)	1.39 (1.31 to 1.46)	0.75 (0.70 to 0.79)
Other	0.69 (0.66 to 0.73)	0.86 (0.81 to 0.92)	0.57 (0.53 to 0.60)
Cause of ESRD			
Diabetes	1.37 (1.32 to 1.42)	0.98 (0.93 to 1.04)	1.82 (1.73 to 1.91)
Dialysis exposure, yr			
≤1	1.00	1.00	1.00
1.1–3	1.24 (1.17 to 1.31)	1.16 (1.08 to 1.24)	1.32 (1.22 to 1.43)
3.1–5	1.39 (1.32 to 1.47)	1.19 (1.10 to 1.28)	1.63 (1.50 to 1.76)
>5	1.67 (1.58 to 1.77)	1.27 (1.18 to 1.38)	2.22 (2.05 to 2.40)
Peak PRA			
0	1.00	1.00	1.00
1–30	1.05 (1.01 to 1.10)	1.03 (0.98 to 1.10)	1.07 (1.01 to 1.13)
31–80	1.08 (1.03 to 1.14)	1.10 (1.03 to 1.18)	1.06 (0.99 to 1.14)
>80	1.24 (1.17 to 1.31)	1.28 (1.19 to 1.38)	1.20 (1.12 to 1.31)
KDPI quartile, %			
0–25	1.00	1.00	1.00
26–50	1.16 (1.10 to 1.21)	1.13 (1.04 to 1.19)	1.20 (1.11 to 1.29)
51–75	1.49 (1.42 to 1.56)	1.45 (1.35 to 1.55)	1.52 (1.42 to 1.64)
76–100	1.98 (1.88 to 2.08)	2.22 (2.06 to 2.38)	1.78 (1.65 to 1.91)
HLA MM			
0	1.00	1.00	1.00
1–3	1.00 (0.93 to 1.08)	1.10 (0.99 to 1.22)	0.93 (0.84 to 1.03)
4–5	1.04 (0.97 to 1.11)	1.20 (1.09 to 1.32)	0.91 (0.84 to 1.00)
6	1.09 (1.01 to 1.17)	1.29 (1.16 to 1.44)	0.93 (0.84 to 1.03)
Induction			
None	1.06 (1.00 to 1.11)	1.06 (0.98 to 1.13)	1.05 (0.98 to 1.13)
Nondepleting	1.02 (0.98 to 1.07)	1.00 (0.94 to 1.07)	1.04 (0.98 to 1.11)
Depleting	1.00	1.00	1.00
CIT, h			
≤12	1.00	1.00	1.00
13–24	1.10 (1.06 to 1.14)	1.08 (1.02 to 1.14)	1.11 (1.05 to 1.18)
>24	1.14 (1.09 to 1.20)	1.11 (1.04 to 1.19)	1.18 (1.09 to 1.26)
Machine perfusion	1.02 (0.99 to 1.06)	1.04 (0.99 to 1.10)	1.00 (0.95 to 1.06)

HR, hazard ratio; 95% CI, 95% confidence interval; PRA, panel reactive antibody; MM, mismatch.

Descriptive Statistics

DSA-Level Variation in the Use of DCD Donor Kidneys

The number and proportion of DCD donor kidneys among all deceased donor kidneys recovered for transplantation in each of the 58 DSAs were determined.

To understand the DSA-level variation in the use of DCD donors, DSAs were grouped into quartiles on the basis of the proportion of DCD donors among all deceased donors recovered in the DSA during the study period. To determine if differences in waiting for potential donors to progress to neurologic brain death contributed to DSA-level variation in DCD donation, the time (in days) between hospital referral to the OPO and declaration of death was compared between DSA quartiles. To determine an association between OPO performance in NBD donation and DCD donation, we compared the donor conversion rate (the proportion of eligible donors converted to actual NBD donors) reported by the SRTR in 2013–2015 between DSA quartiles. Finally, to determine if acceptance of DCD donors by transplant centers within the DSA contributed to the DSA-level variation in DCD donors, we compared the proportion of DCD kidneys shipped outside the DSA between DSA quartiles.

We plotted the proportion of DCD and NBD donor kidneys discarded in each DSA and determined the correlation between DCD and NBD discard within DSAs using the Pearson Correlation Coefficient. The effect of DSA-level discard practices was determined by comparing the proportions of kidneys discarded in DSAs within the highest and lowest deciles of discard in subgroups defined by total donor WIT, KDPI, use of machine perfusion, and use of a donor kidney biopsy.

Factors Associated with Kidney Discard

The number and proportion of DCD and NBD kidneys discarded were determined in strata defined by donor age (<12, 12–17, 18–39, 40–49, 50–59, 60–64, or ≥65 years old), donor body mass index (<25, 25–29.9, or ≥30 kg/m²), donor race (black or nonblack), donor history of hypertension, donor history of diabetes, donor cause of death (cerebrovascular accident, anoxia, head trauma, or other), donor preterminal serum creatinine (≤1.5 or >1.5 mg/dl), donor hepatitis C antibody positivity, year of donation, use of machine perfusion, and the use of a donor kidney biopsy. In addition, we determined the number and proportion of DCD kidneys discarded in categories of total donor WIT. Categories of total donor WIT were determined on the basis of the underlying distribution of the total donor WIT for DCD kidneys: The cut points of 26, 34, and 48 minutes reflect the 50th, 90th, and 95th percentiles of total donor WIT.

The adjusted odds ratio of discard of DCD kidneys compared with NBD kidneys was determined in a generalized linear model using the logit link. These models account for correlation in use between kidneys

Table 7. Risk of graft loss from any cause in recipients of DCD kidneys with increasing total donor WIT compared with recipients of NBD kidneys in subgroups defined by KDPI

Donor Characteristics	HR (95% CI)			
	KDPI 0%–25%	KDPI 26%–50%	KDPI 51%–75%	KDPI 76%–100%
NBD	1.00	1.00	1.00	1.00
DCD WIT, min				
10–26	1.01 (0.86 to 1.19)	0.98 (0.86 to 1.10)	0.93 (0.83 to 1.05)	0.91 (0.78 to 1.06)
27–34	0.97 (0.75 to 1.25)	0.82 (0.68 to 0.99)	0.99 (0.85 to 1.15)	1.07 (0.91 to 1.27)
35–48	0.87 (0.60 to 1.26)	1.19 (0.96 to 1.48)	1.17 (0.98 to 1.40)	0.95 (0.75 to 1.21)
>48	0.96 (0.66 to 1.40)	1.32 (1.00 to 1.75)	1.28 (1.02 to 1.60)	1.28 (0.96 to 1.70)

Separate multivariate Cox regression models adjusted for differences in recipient age, sex, race, cause of ESRD, pretransplant dialysis exposure, panel reactive antibody, HLA matching, use of antibody induction, CIT, and use of machine perfusion. HR, hazard ratio; 95% CI, 95% confidence interval.

from the same donor.²⁴ The regression models adjusted for differences in individual factors within the KDPI equation (donor age, race, diabetes, hypertension, cause of death, hepatitis C antibody positivity, pre-terminal serum creatinine, body mass index in kilograms per square meter, year of donation, use of machine perfusion, and use of a donor kidney biopsy). Similar models were used to determine the adjusted odds ratio of discard of DCD kidneys in successively longer categories of total donor WIT compared with NBD donor kidneys. Additional subgroup analyses were stratified by quartile of the KDPI.

Risk of Graft Loss

Cumulative incidence curves were used to determine the time to allograft failure from ACGL, DCGL, and DWFG in DCD transplant recipients stratified by total donor WIT compared with NBD kidneys. Group differences were determined by the log rank test.

Separate Cox multivariate regression models were used to determine the independent association of donor type (DCD subgrouped by duration of total donor WIT compared with NBD) with allograft failure from any cause, including death, DCGL, and DWFG after adjustment for differences in recipient factors (age, sex, race, cause of ESRD, duration of pretransplant dialysis exposure, and panel reactive antibody), transplant factors (HLA mismatch, use of induction therapy, CIT, and the use of machine perfusion), and donor factors summarized by KDPI quartile. In the models, the intercluster correlation between deceased donor kidneys from the same donor was accounted for using the robust sandwich covariance matrix.^{25,26}

For all Cox models, variables with missing data were assigned a category of missing, and the proportional hazards assumptions were tested using log-negative-log plots of the within-group survivorship probabilities versus log time.

All analyses were performed in SAS 9.4 (Cary, NC).

ACKNOWLEDGMENTS

John Gill is supported by a Foundation Grant from the Canadian Institutes of Health Research.

DISCLOSURES

None.

REFERENCES

1. Israni AK, Zaun D, Bolch C, Rosendale JD, Schaffhausen C, Snyder JJ, Kasiske BL: OPTN/SRTR 2015 annual data report: Deceased organ donation. *Am J Transplant* 17: 503–542, 2017
2. Kootstra G, Daemen JH, Oomen AP: Categories of non-heart-beating donors. *Transplant Proc* 27: 2893–2894, 1995
3. Reese PP, Harhay MN, Abt PL, Levine MH, Halpern SD: New solutions to reduce discard of kidneys donated for transplantation. *J Am Soc Nephrol* 27: 973–980, 2016
4. Johnson RJ, Bradbury LL, Martin K, Neuberger J; UK Transplant Registry: Organ donation and transplantation in the UK—the last decade: A report from the UK national transplant registry. *Transplantation* 97 [Suppl 1]: S1–S27, 2014
5. Sung RS, Christensen LL, Leichtman AB, Greenstein SM, Distant DA, Wynn JJ, Stegall MD, Delmonico FL, Port FK: Determinants of discard of expanded criteria donor kidneys: Impact of biopsy and machine perfusion. *Am J Transplant* 8: 783–792, 2008
6. Singh SK, Kim SJ: Epidemiology of kidney discard from expanded criteria donors undergoing donation after circulatory death. *Clin J Am Soc Nephrol* 11: 317–323, 2016
7. Reich DJ, Mulligan DC, Abt PL, Pruett TL, Abecassis MM, D'Alessandro A, Pomfret EA, Freeman RB, Markmann JF, Hanto DW, Matas AJ, Roberts JP, Merion RM, Klintmalm GB; ASTS Standards on Organ Transplantation Committee: ASTS recommended practice guidelines for controlled donation after cardiac death organ procurement and transplantation. *Am J Transplant* 9: 2004–2011, 2009
8. Burcin Taner C, Bulatao IG, Perry DK, Sibulesky L, Wllingham DL, Kramer DJ, Nguyen JH: Agonal period in donation after cardiac death donors. *Transpl Int* 26: e17–e18, 2013
9. Levvey BJ, Westall GP, Kotsimbos T, Williams TJ, Snell GI: Definitions of warm ischemic time when using controlled donation after cardiac death lung donors. *Transplantation* 86: 1702–1706, 2008
10. Ho KJ, Owens CD, Johnson SR, Khwaja K, Curry MP, Pavlakis M, Mandelbrot D, Pomposelli JJ, Shah SA, Saidi RF, Ko DS, Malek S, Belcher J, Hull D, Tullius SG, Freeman RB, Pomfret EA, Whiting JF, Hanto DW, Karp SJ: Donor postextubation hypotension and age correlate with outcome after donation after cardiac death transplantation. *Transplantation* 85: 1588–1594, 2008
11. Organ Procurement and Transplantation Network: Available at: <http://optn.transplant.hrsa.gov>. Accessed February 1, 2017
12. Bernat JL, D'Alessandro AM, Port FK, Bleck TP, Heard SO, Medina J, Rosenbaum SH, Devita MA, Gaston RS, Merion RM, Barr ML, Marks WH, Nathan H, O'Connor K, Rudow DL, Leichtman AB, Schwab P, Ascher NL, Metzger RA, Mc Bride V, Graham W, Wagner D, Warren J, Delmonico FL: Report of a national conference on donation after cardiac death. *Am J Transplant* 6: 281–291, 2006
13. D'Alessandro AM, Fernandez LA, Chin LT, Shames BD, Turgeon NA, Scott DL, Di Carlo A, Becker YT, Odorico JS, Knechtle SJ, Love RB,

- Pirsch JD, Becker BN, Musat AI, Kalayoglu M, Sollinger HW: Donation after cardiac death: The University of Wisconsin experience. *Ann Transplant* 9: 68–71, 2004
14. Reid AW, Harper S, Jackson CH, Wells AC, Summers DM, Gjorgijmajkoska O, Sharples LD, Bradley JA, Pettigrew GJ: Expansion of the kidney donor pool by using cardiac death donors with prolonged time to cardiorespiratory arrest. *Am J Transplant* 11: 995–1005, 2011
 15. Allen MB, Billig E, Reese PP, Shults J, Hasz R, West S, Abt PL: Donor hemodynamics as a predictor of outcomes after kidney transplantation from donors after cardiac death. *Am J Transplant* 16: 181–193, 2016
 16. Suntharalingam C, Sharples L, Dudley C, Bradley JA, Watson CJ: Time to cardiac death after withdrawal of life-sustaining treatment in potential organ donors. *Am J Transplant* 9: 2157–2165, 2009
 17. Scalea JR, Redfield RR, Arpali E, Levenson GE, Bennett RJ, Anderson ME, Kaufman DB, Fernandez LA, D'Alessandro AM, Foley DP, Mezrich JD: Does DCD donor time-to-death affect recipient outcomes? Implications of time-to-death at a high-volume center in the United States. *Am J Transplant* 17: 191–200, 2017
 18. Singh SK, Kim SJ: Does expanded criteria donor status modify the outcomes of kidney transplantation from donors after cardiac death? *Am J Transplant* 13: 329–336, 2013
 19. Snoeijs MG, Winkens B, Heemskerk MB, Hoitsma AJ, Christiaans MH, Buurman WA, van Heum LW: Kidney transplantation from donors after cardiac death: A 25-year experience. *Transplantation* 90: 1106–1112, 2010
 20. Weber M, Dindo D, Demartines N, Ambühl PM, Clavien PA: Kidney transplantation from donors without a heartbeat. *N Engl J Med* 347: 248–255, 2002
 21. Summers DM, Johnson RJ, Allen J, Fuggle SV, Collett D, Watson CJ, Bradley JA: Analysis of factors that affect outcome after transplantation of kidneys donated after cardiac death in the UK: A cohort study. *Lancet* 376: 1303–1311, 2010
 22. Locke JE, Segev DL, Warren DS, Dominici F, Simpkins CE, Montgomery RA: Outcomes of kidneys from donors after cardiac death: Implications for allocation and preservation. *Am J Transplant* 7: 1797–1807, 2007
 23. Summers DM, Johnson RJ, Hudson A, Collett D, Watson CJ, Bradley JA: Effect of donor age and cold storage time on outcome in recipients of kidneys donated after circulatory death in the UK: A cohort study. *Lancet* 381: 727–734, 2013
 24. Zeger SL, Liang KY, Albert PS: Models for longitudinal data: A generalized estimating equation approach. *Biometrics* 44: 1049–1060, 1988
 25. Lin DY: Cox regression analysis of multivariate failure time data: The marginal approach. *Stat Med* 13: 2233–2247, 1994
 26. Lee EW, Wei LJ, Amato DA: Cox-type regression analysis for large numbers of small groups of correlated failure time observations. In: *Survival Analysis: State of the Art*, edited by Klein JP, Goel PK, Dordrecht, The Netherlands, Kluwer Academic Publishers, 1992, pp 237–247